Leunca (Solanum nigrum L.) herb sensitizes doxorubicin resistant MCF-7 cells
Penulis/Author
Dr. Riris Istighfari Jenie, M.Si., Apt. (1); apt. Rumiyati, S.Si., M.Si., Ph.D. (2); Prof. Dr.rer.nat. apt. Adam Hermawan, S.Farm., M.Sc. (3); Prof. Dr. apt. Edy Meiyanto, M.Si. (4)
Tanggal/Date
2016
Kata Kunci/Keyword
Abstrak/Abstract
Chemotherapeutic agent resistance is becoming a heavy obstacle in cancer therapy as it increases the toxicity of the drug to normal cells and reduces the efficacy of the drug to cancer cells. The molecular mechanism of resistance may involve Pgp protein, a transmembrane protein which has been known to induce efflux of its substrates, including chemotherapeutic drugs, from the cells. One idea to overcome this problem is by combining the chemotherapeutic agent with other substance in order to sensitize cancer cells. Leunca (Solanum nigrum L.) is a potential source of natural anticancer agent. Leunca ethanolic extract (LHE) has cytotoxic activity in several cancer cell lines such as HepG2 and HT-29. The aims of this research were to investigate the effect of leunca ethanolic extract (LHE) in combination with a chemotherapeutic agent, doxorubicin, on MCF-7/doxorubicin resistant (MCF7/DOX) cell line viability and observing the expression level of Pgp protein after combination treatment. Cell viability assay of LHE and its combination with doxorubicin were conducted using MTT [3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide] assay. Pgp expression levels were observed using immunocytochemistry. LHE showed cytotoxic effect on MCF-7/DOX cell line with IC50 344 ?g/ml. Combination of 0.375 (1/16 IC50) and 0.75 ?M (1/8 IC50) doxorubicin with 21.5 (1/16 IC50) and 43 ?g/ml (1/8 IC50) LHE showed strong synergistic effect (CI is 0.1-0.3). The immunocytochemistry results showed that the combination treatment reduced the expression level of Pgp while the doxorubicin treatment increased Pgp expression level. These results suggested that LHE is potential to be developed as co-chemotherapeutic agent on breast cancer cells.
